Clinical trials: B Cell Malignancies
B-cell Malignancy
Phase I Study of HRS-1635 in B-cell Malignancies
The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D).
- Trial name
- NCT07583212
- Testing
- HRS-1635
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Diffuse Large B-cell Lymphoma
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r DLBCL who have received two or more lines of systemic…
- Trial name
- NCT03876028
- Testing
- Tisagenlecleucel, Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Follicular Lymphoma, Marginal Zone Lymphoma
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients…
- Trial name
- SIDNEY (NCT04669171)
- Testing
- EO2463, lenalidomide, rituximab
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Enterome
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
To assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib.
- Trial name
- BOSS (NCT06839872)
- Testing
- Pirtobrutinib, Acalabrutinib
- Sponsor
- AstraZeneca
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell…
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Trial name
- NCT05121103
- Testing
- EZM0414
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Epizyme, Inc.
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: can a dose of JNJ-90009530 be determined that is safe and well…
- Trial name
- NCT05784441
- Testing
- JNJ-90009530
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
- Trial name
- NCT06152575
- Testing
- Elranatamab, Elotuzumab, Pomalidomide
- Where
- 270 sites in United States, Argentina and 25 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
B-cell Small Lymphocytic Lymphoma Recurrent
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
This was a Phase 1 multicenter study of bendamustine, rituximab and TRU-016 (BRT) in subjects with relapsed indolent B-cell lymphoma.
- Trial name
- NCT01317901
- Testing
- TRU-016, Bendamustine, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aptevo Therapeutics
Chronic Lymphocytic Leukemia (CLL)
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
This study will evaluate effectiveness and safety in routine clinical practice in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
- Trial name
- REVEAL (NCT03659669)
- Where
- 13 sites in Israel
- Volunteers
- 272 people
- Sponsor
- AbbVie
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
- Trial name
- PERSIST (NCT07474051)
- Testing
- UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123
- Where
- 5 sites in Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Diffuse Large B Cell Lymphoma
YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
This study is a one-arm, open, multicenter phase 1b/2 clinical trial of YY-20394 combined with GEMOX second-line or above in patients with relapsed and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT04500561
- Testing
- YY-20394
- Volunteers
- 28 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
B-cell Lymphoma
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
- Trial name
- NCT06566586
- Testing
- TQB3702 tablets+Chemotherapy regimen
- Where
- 30 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Lymphocytic Leukemia
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
The study is a Phase 1b open label, non-randomized, single institution clinical trial that is designed to evaluate the safety and tolerability of three repeat infusions of ISF35 followed by a standard regimen of three cycles of…
- Trial name
- NCT00772486
- Testing
- ISF35
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Memgen, LLC
Diffuse Large B Cell Lymphoma
TREatment of degeNerative and Neoplastic Diseases With Rituximab
This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of PBO-326 (Rituximab) and Mabthera (Rituximab) in…
- Trial name
- TREND (NCT01277172)
- Testing
- Rituximab
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- Probiomed S.A. de C.V.
Leukemia
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00086775
- Testing
- alemtuzumab, rituximab, fludarabine phosphate
- Where
- 5 sites in United States
- Sponsor
- Bayer
B-cell Non-Hodgkin Lymphoma
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with…
- Trial name
- NCT03677141
- Testing
- Mosunetuzumab, Polatuzumab Vedotin, Rituxumab
- Where
- 41 sites in United States, Austria and 4 more
- Volunteers
- 117 people
- Sponsor
- Hoffmann-La Roche
Large B-cell Lymphoma
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
This is a study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) in participants aged 18 to < 80 years of age with previously untreated large B-cell…
- Trial name
- Soundtrack D3 (NCT07911553)
- Testing
- Surovatamig, Rituximab, Cyclophosphamide
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
This study has 3 parts. The purpose of Part 1 of this study is to assess the safety and efficacy of brentuximab vedotin in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (known as…
- Trial name
- NCT01925612
- Testing
- brentuximab vedotin, rituximab, vincristine
- Where
- 51 sites in United States, Czechia and 3 more
- Volunteers
- 87 people
- Sponsor
- Seagen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.